Oramed Pharmaceuticals Inc. (NasdaqCM: ORMP)
Health Care · Pharmaceuticals · US
$5.34
+11.02% today · +121.7% 1Y
Oramed Pharmaceuticals Inc. (NasdaqCM: ORMP) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $200.08M and employs 13 people.
Over the last twelve months the share price has gained 121.7%, trading between 2.06 and 5.19.
Tweenvest scores Oramed Pharmaceuticals Inc. across four factors: quality 42/100. Its strongest factor is quality.
ORMP price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $200.08M
- Revenue (TTM)
- $0.00
- P/E
- 1.16
- EPS
- 4.15
- Dividend yield
- —
- Beta (5Y)
- 1.16
- 52-week high
- $5.19
- 52-week low
- $2.06
- Avg volume (3M)
- —
- Shares outstanding
- 41.60M
- Employees
- 13
- Next earnings
- —
About Oramed Pharmaceuticals Inc.
Oramed Pharmaceuticals Inc., founded in 2002 and based in New York, New York, specializes in the development of groundbreaking pharmaceutical treatments. Their primary focus is on creating orally ingested capsules or pills for the delivery of polypeptides, particularly aimed at managing diabetes. The company's leading product, ORMD-0801, is an oral insulin capsule that has successfully completed Phase II clinical trials for patients with diabetes. Oramed is also advancing ORMD-0901, an oral glucagon-like peptide-1 (GLP-1) capsule, which has concluded Phase I clinical trials for the treatment of type 2 diabetes. Additionally, an oral leptin capsule for weight loss is currently under development. The firm was originally incorporated as Integrated Security Technologies, Inc., before officially changing its name to Oramed Pharmaceuticals Inc. in April 2006.
- ISIN
- US68403P2039
- Founded
- 2002
- Listed since
- May 1, 2007
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.10T | $1,189.41 | -3.59% |
| Johnson & JohnsonNYSE: JNJ | $658.24B | $270.00 | -1.15% |
| Merck & Co., Inc.NYSE: MRK | $385.99B | $153.10 | -2.14% |
| Roche Holding AGSWX: ROP | $371.62B | CHF368.30 | -1.47% |
| Novartis AGSWX: NOVN | $303.81B | CHF128.34 | +1.25% |
| AstraZeneca PLCLSE: AZN | $263.84B | £122.34 | -1.94% |
| Novo Nordisk A/SCPSE: NOVO B | $212.51B | Dkr307.80 | +2.86% |
| Pfizer Inc.NYSE: PFE | $162.84B | $28.30 | -0.95% |
Figures last refreshed Aug 18, 2026.